ABRAXANE 5 mg/ml, powder for injectable dispersion for infusion bottle
Active ingredients: Paclitaxel
Commercialized according to BDPMDispensing in France: Prescription only
Powder for injectable dispersion for infusionbottleintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ABRAXANE 5 mg/mL, poudre pour dispersion injectable pour perfusion
- Pharmaceutical form
- poudre pour dispersion injectable pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 100 mg
- Marketing authorisation holder
- BRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 10 Feb 2011
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68739019CIP73844187CIP133400938441871Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PACLITAXELpoudre | 100 mg · un flacon | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.